His areas of Specialization
The field of gerontology has witnessed significant research findings and great development courtesy of Mikhail Blagosklonny’s passion for working with older persons. Over the years, he has developed an intrinsic urge to do more research on molecular and cell biology. It has since led him to the very depths of understanding the cancer therapeutics and following therapeutic strategies. That notwithstanding, Dr. Mikhail has also risen as a pre-eminent researcher with an acute understanding of tissue-specific cancer therapy and the much sophisticated decelerating organism-based aging. Formerly, he worked as an oncologist at Roswell Park Cancer Institute where his significant efforts in cancer and aging fields.
Working on the TOR Signaling
As a professor, he formulated the hypothesis that regarded the pivotal role of Target of Rapamycin signaling that signifies the behavior of cellular reactions to the availability of energy and nutrients. The development has led to the extension of lives for most cancer patients struggling with chronic levels of cancer. As a passionate advocate of TOR signaling, he has remained a pillar in developing other oncological-based practices. Through this advocacy, he Dr. Mikhail has gained immense recognition with most cancer agencies banking on the rapamycin remedy for lengthening the lives of patients on the verge of dying. To date, his research areas have constituted cancer remedies protecting a patient’s healthy cells from any damage. Nevertheless, he has also developed the keen interest in biogerontology where he specializes in developing anti-aging antidotes protecting the general mechanisms beneath the skin from excessive and undue pressure.
Mikhail Blagosklonny’s Startling Career
About his career, he holds a Masters Degree in Internal Medicine and Doctorate in Cardiology experimental medicine both from Pavlov State University. In the year 200, he became an associate medicine professor at New York Medical College, where he worked until 2002. By October 2002, he was appointed as a senior scientist based in Ordway Research Institute where he worked until April 2009 when he took up a job at Roswell Park Cancer Institute. At the center, he has continued with his sterling performances in this area through his continued advocacies for testing and improvement of cancer screening strategies and means of detection. As a visionary leader in this field, his continued research at the institute has revealed the need for cancer therapies to be tailored in many aspects. One is in a way that it meets the precise mutations existing within a patient’s tumor.
Apart from His Oncological Practice
Apart from his distinguished career as an oncologist, he is also an author of various publications that comprise: research and peer-reviewed articles, books and a columnist for various medical publications. He is credited with founding the Cell Cycle, which he became its founding editor in chief. At Cancer Biology and Therapy, he acts as the Associate Editor specializing in Cell Death and Differentiation. He also significantly contributes to International Journal of Cancer and American Journal of Pathology where he writes about cancer therapy strategies. In his contribution to other associated remedies for old age conditions, he also offers free guidance and counseling for patients whenever he finds time for the same.